Comprehensive Evaluation of Gastrointestinal Factors Influencing the Stability and Function of mRNA‐Encapsulated Lipid Nanoparticles
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 23.09.2026. Verfasst von Toma Shinkai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: RNA, Messenger, Nanoparticles, Lipids, Gastrointestinal Tract. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research.
Abstract (Originalsprache)
Owing to the intrinsic instability of mRNA, its routes of administration are limited, and to date, only injectable delivery has been clinically applied. In contrast, oral administration exposes mRNA to a variety of substances in the gastrointestinal (GI) tract. Despite these challenges, oral delivery remains the most familiar and convenient route for patients, making the development of orally administrable mRNA‐encapsulated lipid nanoparticles (mRNA–LNPs) highly desirable. However, no studies have directly examined how mRNA–LNPs are affected within the GI environment. In the present study, we investigated the effects of representative GI components on mRNA–LNPs. Among several digestive enzymes, pepsin markedly reduced the protein‐expression efficiency of the particles, whereas amylase had no effect. Pepsin‐treated particles exhibited increased size, suggesting that structural alterations contributed to the observed functional loss. Lipase at high concentrations impaired nanoparticle function. Because lipase hydrolyzes ester bonds in lipids, we examined LNPs incorporating C12‐200, an ionizable lipid lacking ester bonds, instead of SM‐102. The C12‐200 formulation showed reduced susceptibility to lipase‐induced functional loss, indicating that enzymatic lipid degradation underlay the observed effects. Simulated gastric fluid also significantly diminished particle functionality. A detailed analysis of the relationship between functionality and pH revealed that impairment primarily occurred at approximately pH 1 but not at pH ≥ 3. Collectively, these findings identify the key GI factors that compromise mRNA–LNP integrity and provide important insights into the rational design of orally administrable mRNA–LNP formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt.
ORCID-Profile: Koki Ogawa, Mohamed S Mohamed, Tetsuya Ozeki
Förderung
- Japan Society for the Promotion of Science
- Takeda Science Foundation
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
Zitieren
APA
Shinkai, T., Ogawa, K., Mohamed, M. S., & Ozeki, T. (2026). Comprehensive Evaluation of Gastrointestinal Factors Influencing the Stability and Function of mRNA‐Encapsulated Lipid Nanoparticles. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70392
Vancouver
Shinkai T, Ogawa K, Mohamed MS, Ozeki T. Comprehensive Evaluation of Gastrointestinal Factors Influencing the Stability and Function of mRNA‐Encapsulated Lipid Nanoparticles. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70392
BibTeX
@article{Shinkai2026,
author = {Shinkai, Toma and Ogawa, Koki and Mohamed, Mohamed S and Ozeki, Tetsuya},
title = {Comprehensive Evaluation of Gastrointestinal Factors Influencing the Stability and Function of mRNA‐Encapsulated Lipid Nanoparticles},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70392}
}
EUVIMED